Hinova Pharmaceuticals Inc., a biotech firm headquartered in Chengdu and listed on the Shanghai Stock Exchange (SHA: 688302), has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 chemical drug candidate, HP515. The molecule is intended for the treatment of nonalcoholic steatohepatitis (NASH).
HP515 is a thyroid hormone receptor beta (THR-β) agonist, designed to directly influence gene transcription pathways activated by THR-β. This action is expected to enhance liver cell lipid metabolism, improve the metabolism of liver fat, and reduce lipid toxicity, thereby addressing the underlying issues in NASH.
Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver condition intricately linked to insulin resistance and genetic factors. The condition encompasses a range of liver injuries, from non-alcoholic steatosis to NASH, cirrhosis related to NASH, and hepatocellular carcinoma (HCC). To date, no similar product has been approved for use in China. However, MGL-3196 (resmetirom), a drug for the treatment of NASH with liver fibrosis, received approval in the United States in March of this year, marking a significant development in the global therapeutic landscape for NASH.- Flcube.com
